Cellectis Presents Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Overcoming Key Challenges of Targeting Solid Tumors at SITC 2022

Rhea-AI Summary

Cellectis, a clinical-stage biotechnology company, announced the presentation of preclinical data on TALEN®-edited smart CAR T-cells at the SITC 37th Annual Meeting. The data, focusing on targeting solid tumors, includes two key presentations about MUC-1 CAR T-cells and T-cell engineering strategies that improve anti-tumor efficacy while minimizing toxicity. The innovative approaches address challenges faced by CAR T-cell therapies in solid tumors, particularly triple-negative breast cancer. The presentations are available on Cellectis' website following the event.

Positive

• Presentation of innovative preclinical data on TALEN®-edited CAR T-cells targeting solid tumors.
• Evidence suggests enhanced efficacy of MUC-1 CAR T-cells in controlling triple-negative breast cancer.
• TALEN® platform shows promise in overcoming challenges of CAR T-cell therapies in solid tumors.
• Potential for increased CAR T cell persistence and anti-tumor activity while mitigating safety risks.

Negative

• None.

NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) --  Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that preclinical data will be presented on TALEN®-edited smart CAR T-cells overcoming key challenges of targeting solid tumors at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting.

The data will be presented today in two poster sessions titled: “Multi-armored allogeneic MUC-1 CAR T-cells efficiently control triple negative breast cancer tumor growth” (Poster Number: 217) and “TALEN®-edited smart CAR T-cells leverage solid tumor microenvironment for specific and effective immunotherapy” (Poster Number: 325).

The poster presentations highlight the following preclinical data:

Multi-armored allogeneic MUC-1 CAR T-cells efficiently control triple negative breast cancer tumor growth

• This poster highlights TALEN®-edited smart CAR T-cells targeting MUC1- expressing solid tumors.
  
• MUC1 is a tumor-associated antigen that is overexpressed in triple-negative breast cancer (TNBC) and other solid tumor malignancies.
  
• MUC-1 CAR T-cells infiltrate tumors more efficiently and extend survival when enhanced with attributes catered towards the tumor microenvironment (TME) of TNBC tumors.
  
• TGFBR2 knock-out (KO) circumvents the inhibitory effects of TGFβ1, and IL-12 release follows CAR T-cell activation pattern restricting it to the tumor site for increased safety.
  
• Enhanced MUC-1 CAR T-cells could address some of the current challenges in development of CAR Ts for TNBC patients with unmet medical needs.
  
• Overall, we can efficiently generate allogeneic CAR T-cells and engineer them to overcome several key challenges of immune suppressive solid tumors.

TALEN®-edited smart CAR T-cells leverage solid tumor microenvironment for specific and effective immunotherapy

• This poster highlights innovative T-cell engineering strategies designed to increase the activity of CAR T-cells for solid tumors while mitigating toxicity risk.
  
• Therapeutic efficacy of CAR T-cell therapy has so far been restricted to only a few malignancies, with solid tumors proving to be especially recalcitrant to efficient therapy. Our TALEN®-based gene editing platform allows innovative T cell engineering strategies that can combat some of the challenges posed by CAR T cell development for solid tumors.
  
• Inducible expression of a tumor-antigen directed CAR by a constitutive CAR specific to TME cues greatly enhanced anti-tumor activity, while limiting ‘on target, off-tumor’ cytotoxicity. Additionally, CAR-induced gene expression could boost anti-tumor CART only within the TME.
  
• Cellectis’ gene editing strategies could increase CAR T cell persistence and anti-tumor activity while staying restricted to the tumor milieu.
  
• This proof-of-concept study demonstrates the feasibility of developing CART cell engineering strategies that can improve solid tumor targeting while mitigating potential safety risks, paving the way for clinical development.
  

Laurent Poirot, Ph.D., Senior Vice President Immunology at Cellectis, noted:

“Using our TALEN®-based gene editing platform, we have presented innovative T cell engineering strategies that can combat some of the challenges posed by CAR T cell development for solid tumors. We are mitigating potential safety risks, paving the way for clinical development for patients with unmet medical needs.”

Presentations will occur today, from 9:00AM until 9:00PM ET, Hall C.

A copy of both poster presentations will be available on Cellectis’ website here, shortly after the event.

About Cellectis
Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. Cellectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to make therapeutic gene editing in hemopoietic stem cells for various diseases. As a clinical-stage biopharmaceutical company with over 22 years of experience and expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN^®, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to treat diseases with unmet medical needs. Cellectis’ headquarters are in Paris, France, with locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).

For more information, visit www.cellectis.com. Follow Cellectis on social media: @cellectis, LinkedIn and YouTube.

For further information, please contact:  

Media contacts:  
Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com
Margaret Gandolfo, Senior Manager, Communications, +1 (646) 628 0300  

Investor Relation contact:  
Arthur Stril, Chief Business Officer, +1 (347) 809 5980, investors@cellectis.com  
Ashley R. Robinson, LifeSci Advisors, +1 617 430 7577

Forward-looking Statements

This press release contains “forward-looking” statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as “anticipate,” “believe,” “intend”, “expect,” “plan,” “scheduled,” “could,” “may” and “will,” or the negative of these and similar expressions. These forward-looking statements, which are based on our management’s current expectations and assumptions and on information currently available to management. Forward-looking statements include statements about the potential of our preclinical programs and product candidates. These forward-looking statements are made in light of information currently available to us and are subject to numerous risks and uncertainties, including with respect to the numerous risks associated with biopharmaceutical product candidate development. With respect to our cash runway, our operating plans, including product development plans, may change as a result of various factors, including factors currently unknown to us. Furthermore, many other important factors, including those described in our Annual Report on Form 20-F and the financial report (including the management report) for the year ended December 31, 2021 and subsequent filings Cellectis makes with the Securities Exchange Commission from time to time, as well as other known and unknown risks and uncertainties may adversely affect such forward-looking statements and cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

Attachment

• SITC_ DATA PR

FAQ

What were the key findings from Cellectis' recent data presentation at SITC 2022?

Cellectis presented preclinical data showing that TALEN®-edited smart CAR T-cells effectively target solid tumors and improve anti-tumor activity, particularly in triple-negative breast cancer.

How does Cellectis' TALEN® platform enhance CAR T-cell therapy?

The TALEN® platform allows for innovative T-cell engineering strategies that address challenges in CAR T-cell therapy for solid tumors by improving efficacy and reducing toxicity.

What specific type of cancer was targeted in the Cellectis presentation?

The presentation primarily focused on triple-negative breast cancer (TNBC) and solid tumors expressing the MUC1 antigen.

When and where was the data presented by Cellectis?

The data was presented on November 10, 2022, at the Society for Immunotherapy of Cancer’s 37th Annual Meeting.

What is the significance of the findings for patients with solid tumors?

The findings suggest potential advancements in CAR T-cell therapies for patients with solid tumors, particularly those with unmet medical needs.